Frampton CMA - Search Results

1

Fibrinogen and hemoglobin predict near future cardiovascular events in asymptomatic individuals.

Lassé M, Pilbrow AP, Kleffmann T, Andersson Överström E, von Zychlinski A, Frampton CMA, Poppe KK, Troughton RW, Lewis LK, Prickett TCR, Pemberton CJ, Richards AM, Cameron VA. Lassé M, et al. Among authors: frampton cma. Sci Rep. 2021 Feb 25;11(1):4605. doi: 10.1038/s41598-021-84046-7. Sci Rep. 2021. PMID: 33633217 Free PMC article.

2

Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure.

Richards AM, Crozier IG, Espiner EA, Ikram H, Yandle TG, Kosoglou T, Rallings M, Frampton C. Richards AM, et al. J Cardiovasc Pharmacol. 1992;20(5):735-41. J Cardiovasc Pharmacol. 1992. PMID: 1280735 Clinical Trial.

3

Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers.

Richards AM, Wittert GA, Espiner EA, Yandle TG, Ikram H, Frampton C. Richards AM, et al. Circ Res. 1992 Dec;71(6):1501-7. doi: 10.1161/01.res.71.6.1501. Circ Res. 1992. PMID: 1423942 Clinical Trial.

4

Prolonged inhibition of endopeptidase 24.11 in normal man: renal, endocrine and haemodynamic effects.

Richards AM, Wittert G, Espiner EA, Yandle TG, Frampton C, Ikram H. Richards AM, et al. J Hypertens. 1991 Oct;9(10):955-62. J Hypertens. 1991. PMID: 1658138 Clinical Trial.

5

EC 24.11 inhibition in man alters clearance of atrial natriuretic peptide.

Richards AM, Wittert G, Espiner EA, Yandle TG, Frampton C, Ikram H. Richards AM, et al. J Clin Endocrinol Metab. 1991 Jun;72(6):1317-22. doi: 10.1210/jcem-72-6-1317. J Clin Endocrinol Metab. 1991. PMID: 1827451 Clinical Trial.

6

Competitive peptide antagonists of ANF-induced cyclic guanosine monophosphate production.

Abell TJ, Richards AM, Yandle TG, Espiner EA, Frampton C, Ikram H. Abell TJ, et al. Biochem Biophys Res Commun. 1989 Oct 16;164(1):108-13. doi: 10.1016/0006-291x(89)91689-6. Biochem Biophys Res Commun. 1989. PMID: 2553010

7

Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man.

Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. Holmes SJ, et al. J Clin Endocrinol Metab. 1993 Jan;76(1):91-6. doi: 10.1210/jcem.76.1.8380606. J Clin Endocrinol Metab. 1993. PMID: 8380606 Clinical Trial.

8

Brain natriuretic peptide: natriuretic and endocrine effects in essential hypertension.

Richards AM, Crozier IG, Holmes SJ, Espiner EA, Yandle TG, Frampton C. Richards AM, et al. J Hypertens. 1993 Feb;11(2):163-70. doi: 10.1097/00004872-199302000-00008. J Hypertens. 1993. PMID: 8385176 Clinical Trial.

9

Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II.

Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, Frampton C. Richards AM, et al. J Hypertens. 1993 Apr;11(4):407-16. doi: 10.1097/00004872-199304000-00011. J Hypertens. 1993. PMID: 8390508 Clinical Trial.

10

Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension.

Richards AM, Crozier IG, Kosoglou T, Rallings M, Espiner EA, Nicholls MG, Yandle TG, Ikram H, Frampton C. Richards AM, et al. Hypertension. 1993 Jul;22(1):119-26. doi: 10.1161/01.hyp.22.1.119. Hypertension. 1993. PMID: 8391513 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

399 results

Search Page

Filters